XtalPi announced on the 20th that it signed a Memorandum of Understanding (MOU) with Korea's leading pharmaceutical company Dong-A ST, to jointly develop...
Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying multiplexable genome editing technology to...
Safety review leading to dose escalation and achievement of first predetermined enrollment target in Phase 1/2 study of SRP-1003 for DM1 triggers $100 ...
Bionova Scientific®, a full-service biologics contract development and manufacturing organization (CDMO) and subsidiary of global conglomerate Asahi ...
Nanotein’s NanoSpark® reagents enhance cell activation and expansion in cell therapy manufacturing Exclusive global distribution agreement...
Breyanzi has the potential to be the first and only CAR T cell therapy approved for MZL, addressing a high unmet need Application based on results fro...
BriaCell Therapeutics Corp. a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority owned s...
Phlow Corp., a leading American pharmaceutical contract development and manufacturing organization (CDMO), and Antheia, the pharmaceutical ingredient man...
AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, highlights the value of its HUB partn...
The U.S. Food and Drug Administration announced it has placed Sarepta Therapeutics investigational gene therapy clinical trials for limb girdle muscular ...
AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing next-generation gene therapies for inherited retinal diseases, ann...
Ultragenyx Pharmaceutical Inc. announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for its Biologics L...
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces a favorable outco...
Golden Age Health Pte. Ltd. (“GAH”) and Innostellar Biotherapeutics Co., Ltd. (“Innostellar”) announced an exclusive ten-ye...
© 2025 Biopharma Boardroom. All Rights Reserved.
